Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine

Respirology. 2023 Mar;28(3):215-216. doi: 10.1111/resp.14395. Epub 2022 Oct 18.

Authors

Bradley A Edwards^{1

2}, Simon A Joosten^{3

4

5}

Affiliations

¹ Department of Physiology, Biomedical Discovery Institute, Monash University, Melbourne, Victoria, Australia.
² Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.
³ Monash Lung, Sleep, Allergy, and Immunity, Monash Health, Clayton, Victoria, Australia.
⁴ School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
⁵ Monash Partners - Epworth, Melbourne, Victoria, Australia.

PMID: 36257913
DOI: 10.1111/resp.14395

No abstract available

Keywords: precision medicine; sleep apnoea; sleep disorders.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Atomoxetine Hydrochloride / therapeutic use
Humans
Precision Medicine*
Sleep
Sleep Apnea, Obstructive* / drug therapy

Substances

Atomoxetine Hydrochloride
oxybutynin